NCT02884960 is a NA clinical trial of Uterine Fibroid Embolization in Uterine Fibroids, sponsored by Gary Siskin, MD.

Who is sponsoring NCT02884960?

NCT02884960 is sponsored by Gary Siskin, MD.

What drugs are being tested in NCT02884960?

Interventions in NCT02884960: Uterine Fibroid Embolization.

What condition does NCT02884960 study?

NCT02884960 studies Uterine Fibroids.

Is NCT02884960 still recruiting?

NCT02884960 is currently status unknown. Last updated 30 August 2016.

Last reviewed 2016-08-30 · How we verify

NCT02884960

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Embozene® Microspheres for Uterine Fibroid Embolization Compared to Embosphere® Microspheres for Symptomatic Relief From Uterine Fibroids

Status unknown NA Last updated 30 August 2016

What this trial tests

NA trial testing Uterine Fibroid Embolization in Uterine Fibroids in 118 participants. Status unknown.

Timeline

1 October 2016

Primary endpoint
1 October 2017

1 October 2018

Quick facts

Lead sponsor	Gary Siskin, MD
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	118
Start date	1 October 2016
Primary completion	1 October 2017
Estimated completion	1 October 2018

Drugs / interventions tested

Uterine Fibroid Embolization

Conditions studied

Uterine Fibroids — all drugs for Uterine Fibroids →

Sponsor

Gary Siskin, MD

Who can join

Adults 30 to 50, female only, with Uterine Fibroids. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Fibroid Infarction Rate
Time frame: 3 Months
The primary effectiveness endpoint for this study is the proportion of patients with a global rate of infarction for all fibroids present within the uterus that is \>90% as seen on contrast-enhanced MRI.

Sponsor's own description

The purpose of this study is to evaluate the safety and effectiveness of Embozene Microspheres compared with Embosphere Microspheres for the treatment of symptomatic uterine fibroids. A total of 118 patents with symptomatic uterine fibroids will be enrolled at 6 sites. Symptom severity, health-related quality of life, and the appearance of the fibroids will be assessed prior to treatment. Patients will then undergo the uterine fibroid embolization procedure with either Embosphere Microspheres or Embozene Microspheres, which will be randomly assigned. Clinical outcomes will be assessed 1 month, 3 months, 6 months and 12 months after the procedure, and imaging outcomes will be obtained 3 months after the procedure.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Updates on Uterine Artery Embolization.
Kohi MP, Spies JB. · · 2018 · cited 38× · PMID 29628616 · DOI 10.1055/s-0038-1636521

Verify or expand the search:

Other recruiting trials for Uterine Fibroids

Currently open trials in the same condition.

NCT07378098 — to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia · Phase 3 · recruiting
NCT07486622 — Transvaginal Electromechanical Fragmentation and Removal of Large Uterus in a Sealed Bag: The First Group of Clinical St · active not recruiting
NCT06671548 — Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids · Phase 3 · recruiting
NCT05448365 — Vitamin D, Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in Uterine Fibroid · NA · recruiting
NCT04126824 — Effect of Addition of Steroids on Duration of Analgesia · EARLY_PHASE1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02884960 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gary Siskin, MD
Last refreshed: 30 August 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02884960.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing